These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 17398194

  • 1. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
    Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R.
    Am J Cardiol; 2007 Apr 01; 99(7):970-3. PubMed ID: 17398194
    [Abstract] [Full Text] [Related]

  • 2. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
    Holme I, Boman K, Brudi P, Egstrup K, Gohlke-Baerwolf C, Kesäniemi YA, Malbecq W, Rossebø AB, Wachtell K, Willenheimer R, Pedersen TR.
    Am J Cardiol; 2010 Jun 15; 105(12):1802-8. PubMed ID: 20538134
    [Abstract] [Full Text] [Related]

  • 3. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators.
    N Engl J Med; 2008 Sep 25; 359(13):1343-56. PubMed ID: 18765433
    [Abstract] [Full Text] [Related]

  • 4. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
    Greve AM, Bang CN, Boman K, Egstrup K, Forman JL, Kesäniemi YA, Ray S, Pedersen TR, Best P, Rajamannan NM, Wachtell K.
    Am J Cardiol; 2018 Mar 15; 121(6):739-745. PubMed ID: 29361285
    [Abstract] [Full Text] [Related]

  • 5. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
    Bang CN, Greve AM, La Cour M, Boman K, Gohlke-Bärwolf C, Ray S, Pedersen T, Rossebø A, Okin PM, Devereux RB, Wachtell K.
    Am J Cardiol; 2015 Dec 15; 116(12):1840-4. PubMed ID: 26602073
    [Abstract] [Full Text] [Related]

  • 6. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
    Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R.
    Am J Cardiol; 2010 Dec 01; 106(11):1634-9. PubMed ID: 21094366
    [Abstract] [Full Text] [Related]

  • 7. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
    Green A, Ramey DR, Emneus M, Iachina M, Stavem K, Bolin K, McNally R, Busch-Sørensen M, Willenheimer R, Egstrup K, Kesäniemi YA, Ray S, Basta N, Kent C, Pedersen TR.
    Am J Cardiol; 2014 Nov 15; 114(10):1518-22. PubMed ID: 25267716
    [Abstract] [Full Text] [Related]

  • 8. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.
    Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K, Gerdts E.
    JACC Cardiovasc Imaging; 2009 Apr 15; 2(4):390-9. PubMed ID: 19580719
    [Abstract] [Full Text] [Related]

  • 9. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events.
    Rieck ÅE, Cramariuc D, Boman K, Gohlke-Bärwolf C, Staal EM, Lønnebakken MT, Rossebø AB, Gerdts E.
    Hypertension; 2012 Jul 15; 60(1):90-7. PubMed ID: 22647889
    [Abstract] [Full Text] [Related]

  • 10. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
    Lund BP, Gohlke-Bärwolf C, Cramariuc D, Rossebø AB, Rieck AE, Gerdts E.
    Am J Cardiol; 2010 May 15; 105(10):1456-60. PubMed ID: 20451694
    [Abstract] [Full Text] [Related]

  • 11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG, Ballantyne CM, Hsueh WA, Rosen JB, Lin J, Shah AK, Tomassini JE, Lowe RS, Tershakovec AM.
    J Clin Lipidol; 2013 May 15; 7(4):292-303. PubMed ID: 23890516
    [Abstract] [Full Text] [Related]

  • 12. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
    Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C.
    Circulation; 2011 Mar 01; 123(8):887-95. PubMed ID: 21321152
    [Abstract] [Full Text] [Related]

  • 13. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 01; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 14. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
    Averna M, Zaninelli A, Le Grazie C, Gensini GF.
    J Clin Lipidol; 2010 Nov 01; 4(4):272-8. PubMed ID: 21122660
    [Abstract] [Full Text] [Related]

  • 15. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
    Bang CN, Greve AM, Boman K, Egstrup K, Gohlke-Baerwolf C, Køber L, Nienaber CA, Ray S, Rossebø AB, Wachtell K.
    Am Heart J; 2012 Apr 01; 163(4):690-6. PubMed ID: 22520536
    [Abstract] [Full Text] [Related]

  • 16. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 01; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 17. Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.
    Lønnebakken MT, De Simone G, Saeed S, Boman K, Rossebø AB, Bahlmann E, Gohlke-Bärwolf C, Gerdts E.
    Heart; 2017 Sep 01; 103(18):1443-1448. PubMed ID: 28455295
    [Abstract] [Full Text] [Related]

  • 18. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy.
    Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S.
    Heart Lung Circ; 2009 Oct 01; 18(5):343-6. PubMed ID: 19586799
    [Abstract] [Full Text] [Related]

  • 19. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study.
    Bang CN, Dalsgaard M, Greve AM, Køber L, Gohlke-Baerwolf C, Ray S, Rossebø AB, Egstrup K, Wachtell K.
    Int J Cardiol; 2013 Oct 03; 168(3):2322-7. PubMed ID: 23416018
    [Abstract] [Full Text] [Related]

  • 20. Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
    Greve AM, Bang CN, Boman K, Egstrup K, Kesäniemi YA, Ray S, Pedersen TR, Wachtell K.
    Am J Cardiol; 2019 Dec 01; 124(11):1736-1740. PubMed ID: 31586530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.